1
**Spatial analysis reveals distinct immune phenotypes and tertiary lymphoid structure-like aggregates in pediatric acute myeloid leukemia**

Joost B. Koedijk[1,2], Inge van der Werf[1,3], Marijn A. Vermeulen[1], Alicia Perzolli[1,2], Marta
Fiocco[1,4,5], Hester A. de Groot-Kruseman[1], Rubina Moeniralam[1], Stefan Nierkens[1,6], Mirjam
E. Belderbos[1], C. Michel Zwaan[1,2#], Olaf Heidenreich[1,7#*]

[1]Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

[2]Department of Pediatric Oncology, Erasmus MC/Sophia Children's Hospital, 3015 GD
Rotterdam, The Netherlands.

[3]Oncode Institute, 3521 AL, Utrecht, The Netherlands

[4]Mathematical Institute, Leiden University, Leiden, The Netherlands

[5]Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The
Netherlands.

[6]Center for Translational Immunology, University Medical Center Utrecht, 3584 CX Utrecht,
The Netherlands.

[7]Wolfson Childhood Cancer Research Centre, Newcastle University, Newcastle upon Tyne
NE1 7RU, UK.

[#]Equal contribution

*Corresponding author: Olaf Heidenreich, Princess Máxima Center for Pediatric Oncology,
3584 CS Utrecht, The Netherlands. Phone: 088-9727272; E-mail:
o.t.heidenreich@prinsesmaximacentrum.nl

**Running title:** The spatial immune landscape of pediatric AML

**Disclosure of conflicts of interest:** The authors declare no financial conflicts of interest.

**Figures/Tables:** 5 Main Figures, 3 Supplementary Figures, 3 Supplementary Tables.

**Words (excl. references):** 4858    **References:** 50

**Keywords:** spatial transcriptomics, bone biopsy, secondary lymphoid organs, ectopic T cell
networks, hematological malignancies.

Koedijk et al.

**Abstract**

Pediatric cancers are characterized by a relatively low mutational burden and therefore, children are thought to be poor candidates for T cell-engaging immunotherapies. Here, we performed a multidimensional characterization of the tumor immune microenvironment in newly diagnosed children with acute myeloid leukemia (AML) and non-leukemic controls. We identified a subset of pediatric AML patients with remarkably high levels of T cell infiltration and a relatively low abundance of anti-inflammatory macrophages in the bone marrow. In addition, we detected large T cell networks that colocalized with B cells in immune-infiltrated samples, resembling tertiary lymphoid structures as described in solid tumors. Using spatial transcriptomics, we dissected the composition of these structures and revealed unique hotspots of anti-tumor immunity. This work raises the possibility that a subset of pediatric AML patients may benefit from T cell-engaging immunotherapies and encourages further study of these lymphoid structures in the context of immunotherapy in AML.

**Statement of significance:** A subset of pediatric AML patients harbors hotspots of anti-tumor immunity in the tumor microenvironment. The presence of tertiary lymphoid structure-like aggregates in the bone marrow of pediatric AML encourages the evaluation of T cell-engaging immunotherapies in this population, as well as the development of novel antibody-based and cellular therapies.

A tumor microenvironment that is infiltrated by cytotoxic T cells is of crucial importance to elicit

a response to T cell-engaging immunotherapies such as immune checkpoint inhibitors and

bispecific antibodies[1]. In contrast, patients with an immune-depleted or 'cold' tumor

microenvironment show significantly reduced response rates. Due to the relatively low

mutational burden and the associated poor immunogenicity of pediatric cancers, children are

thought to be poor candidates for T cell-engaging immunotherapies[2-3]. Among pediatric

cancers, pediatric acute myeloid leukemia (AML) is a cancer with a particularly low mutational

burden[4]. Nonetheless, recent evidence suggests that considerable variation in immune cell

infiltration exists among cancers that are considered to be immunologically 'cold'[4-5]. For

instance, in adult AML, which has a relatively low mutational burden in comparison to other

adult cancer types, *TP53* mutations have been linked to relatively high immune cell infiltration

in the bone marrow (BM) and improved responses to immunotherapy in comparison to *TP53*-

WT adult AML[4,6-7]. However, little is known about the immune compartment in the BM of

pediatric AML patients and clinical trials that evaluate the efficacy of such therapies have only

recently been initiated for this population[8]. Therefore, it is unclear whether children with AML

may be successfully treated with T cell-engaging immunotherapies. This prompted us to

perform a multidimensional characterization of the tumor immune microenvironment in newly

diagnosed children with *de novo* AML and non-leukemic controls. We identify a subset of

patients with remarkably high T cell infiltration in the BM, dissect the spatial immune

organization and specifically, unravel the composition of tertiary lymphoid structure-like

aggregates in the BM of AML, with implications for future immunotherapy approaches.

**Results**

**A subset of pediatric AML patients has remarkably high T cell infiltration in the bone**

**marrow**

For this study, we obtained 53 formalin-fixed and paraffin-embedded (FFPE) bone biopsies

from a representative cohort of pediatric patients with treatment-naïve *de novo* AML (n=43),

and from age- and sex-matched pediatric patients with treatment-naïve early-stage

rhabdomyosarcoma without evidence of malignancy infiltrating the BM (non-leukemic controls,

n=10; **Fig. 1A**). Patient characteristics are depicted in **Table S1**. Using immunohistochemistry

(IHC), we found a decreased abundance of both the overall number of T cells and cytotoxic T

cells in pediatric AML patients in comparison to non-leukemic controls (representative images

are shown in **Fig. 1B-C**; two-sided $P = 0.006$ and $P = 0.003$, respectively; **Fig. 1D-E**). However,

the extent of overall T cell and cytotoxic T cell infiltration could differ up to 90-fold between

individual AML patients, with several patients showing relatively high T cell infiltration in the

BM**.** Because it has previously been shown that cancer cells' genetic alterations may shape

the tumor immune microenvironment, we assessed if certain AML-associated genetic
alterations were linked to the level of T cell infiltration[9]. Interestingly, most of the patients with
relatively high T cell infiltration in the BM had *KMT2A*-rearranged AML, the most common
cytogenetic abnormality in pediatric AML, although there was wide variation among this
cytogenetic subgroup[10]. In contrast, most other cytogenetic groups showed low levels of both
populations with little variation between patients, although several outliers were seen in these
groups as well (**Fig 1F-G**). Collectively, we identified substantial variation in T cell infiltration
in the BM of pediatric AML with a subset of patients showing a remarkably high T cell
frequency in the BM.

**Immune-infiltrated leukemias are characterized by tumor-specific T cell responses and**
**a relatively low abundance of anti-inflammatory macrophages**

To further study pediatric AML patients with a relatively high T cell abundance in the BM, we
dichotomized patients into immune-infiltrated (n=8) and immune-depleted (n=35) groups using
the non-leukemic controls' median value of cytotoxic T cells as the cut-off value. Subsequently,
we performed immune-related gene expression profiling on a cytogenetically representative
subset of immune-infiltrated (n=5) and immune-depleted (n=18) samples. Among this subset,
four out of five (80%) immune-infiltrated samples had a KMT2A-rearrangement, while five out
of eighteen (28%) samples in the immune-depleted group had this cytogenetic abnormality
(**Table S1**). First, we focused on cytotoxicity-related- and immune checkpoint genes since
their expression may give insight into the likelihood of response to immune checkpoint
inhibitors. In our cohort, immune-infiltrated patients showed upregulation of both cytotoxic T
cell genes (*CD8A*, *CD8B*) and cytotoxicity-related genes including *GZMK*, suggestive of
enrichment of GZMK[+] cytotoxic T cells, which has been associated with response to PD-1
blockade in adult AML patients (**Fig. 2A**)[11]. Moreover, pediatric AML patients with an immune-
infiltrated BM highly expressed *TNFRSF9* (encoding CD137) and the immune checkpoint
genes *PDCD1* (encoding PD-1), *CTLA4*, *TIGIT* and *LAG3,* indicative of tumor-specific T cell
responses that may be successfully reinvigorated by immune checkpoint inhibitors (**Fig. 2A**)[12-
13]. Importantly, using a publicly available pediatric AML scRNAseq dataset, we confirmed that
the above-mentioned checkpoint genes are mainly expressed by cytotoxic T cells, and that
*TIGIT* and *LAG3* were the most widely expressed among this population (n=8 patients; **Fig.**
**S1A-E**)[14]. Taken together, these results suggest that pediatric AML patients with an immune-
infiltrated BM may show increased responses to immune checkpoint inhibitors in comparison
to patients with an immune-depleted BM, and that the immune checkpoints TIGIT and LAG-3
may prove suitable targets to enhance cytotoxic T cell function in pediatric AML.

We next investigated whether we could identify differences in factors that either

promote or restrict T cell infiltration in the BM. As anticipated, immune-infiltrated samples had

significantly higher expression of genes related to T cell-attracting chemokines (*CXCL9*,

*CXCL10*), and their corresponding receptor (*CXCR3*; **Fig. 2A**). In line with this, pathway

analysis using GO biological processes indicated that immune-infiltrated samples were

enriched in T cell migratory and -chemotaxis pathways, suggesting that immune-depleted

samples are devoid of signals that attract T cells to the BM (**Fig. 2B**). From solid cancers, we

know that macrophages in the tumor microenvironment are the main regulators of the extent

of T cell infiltration into the tumor[15]. Specifically, pro-inflammatory, M1-like macrophages are

known to be the primary source of T cell-attracting chemokines, while anti-inflammatory, M2-

like macrophages restrict T cell infiltration into the tumor[16]. Previously, a specific M2-like

macrophage signature has been generated for five cancer types including AML and therefore,

we investigated the abundance of M2-like macrophages in our pediatric AML cohort[17].

Interestingly, the estimated abundance of M2-like macrophages was inversely correlated with

both the total T cell and cytotoxic T cell frequency in the BM (Spearman's $r$ = -0.76 [95% CI: -

0.89 to -0.51], $P$ < 0.001, $r$ = -0.64 [95% CI: -0.83 to -0.30], $P$ = 0.001, respectively; **Fig. 2C**

and **Fig. S1F**). Concordantly, we identified a significantly decreased M2-like macrophage

abundance in immune-infiltrated samples compared to immune-depleted samples (two-sided

$P$ < 0.001; **Fig. 2D**). Notably, immune-depleted samples had significantly higher expression

of the gene encoding arginase type II (*ARG2*), which is known to be crucial for AML blast-

mediated polarization of monocytes into an M2-like phenotype[18]. Next, because it is unknown

whether the abundance of M2-like macrophages affects the response to T cell-engaging

immunotherapies in AML, we investigated whether the M2-like macrophage abundance is

associated with poor response upon these therapies. However, pre-treatment gene

expression data from immunotherapy-treated pediatric AML patients were not available and

therefore, we used an immune-related gene expression profiling dataset of pre-treatment BM

samples from 30 refractory or relapsed adult AML patients that were treated with flotetuzumab,

a bispecific CD3 x CD123 antibody, in the context of a clinical trial (CP-MGD006-01;

NCT02152956)[19]. Interestingly, the M2-like macrophage abundance was significantly lower in

patients with anti-leukemic activity (n=12) in comparison to non-responders (n=18; two-sided

$P$ < 0.001; **Fig. 2E**). In fact, the M2-like macrophage abundance outperformed several other

known predictors of response to immunotherapy (area under the receiver operating

characteristic-curve: 0.852 [95% CI 0.71-0.99], $P$ = 0.0012; **Fig. 2F**)[17,20]. In summary, we

identified a relatively low abundance of M2-like macrophages in immune-infiltrated samples.

In addition, we found that the M2-like macrophage abundance in the BM could be used as a

potential biomarker for response to T cell-engaging immunotherapies in AML.

**T cells cluster into spatially organized networks in the bone marrow of pediatric AML**

Intriguingly, IHC performed to quantify the T cell infiltration in the BM revealed large networks of T cells in immune-infiltrated samples. Previously, it has been shown in mice that circulating naïve T cells home to the BM upon intravenous antigen administration, where they form dense networks of T cells and subsequently, are activated and differentiated towards effector and memory cells[21]. Therefore, we investigated the spatial organization of T cells in pediatric immune-infiltrated, immune-depleted, and non-leukemic BM samples. T cell networks were defined as at least 10 directly interacting T cells (≤10 μm between adjacent nuclei), to minimize the chance of classifying randomly dispersed T cells as networks (**Fig. 3A**)[22]. Interestingly, T cell networks were detected in both AML groups and in controls, although significantly more frequent in immune-infiltrated samples compared to immune-depleted samples ($P < 0.001$; **Fig. 3B** and **Table S2**). In fact, there was a strong correlation between the level of T cell infiltration and the number of T cell networks, albeit two out of eight immune-infiltrated patients had a relatively low number of networks (n=53; $r = 0.86$ [95% CI: 0.77-0.92], $P < 0.001$; **Fig. 3C**). Also, with respect to the size of T cell networks, immune-infiltrated samples were the only ones with a multitude of large networks (at least 100 directly interacting T cells; **Fig. 3D**). Remarkably, we noticed that in these biopsies, T cell network areas were largely devoid of AML cells, which could indicate local clearance of AML cells (determined using AML immunophenotypic markers; **Fig. 3E-F**)[23]. In contrast, we did not identify such large T cell networks in the BM of immune-depleted samples (**Fig. 3G-H**). Taken together, these data show that spatially organized networks of T cells are widely abundant in pediatric AML patients with an immune-infiltrated BM, potentially reflecting local priming of anti-tumor immunity and/or immune-mediated elimination of AML cells.

**Spatial transcriptomics reveals localized cellular and humoral immunity in *KMT2A*-rearranged patients**

Subsequently, we wondered whether these large T cell networks in the BM resemble secondary lymphoid organ-like structures, as seen in solid cancers ('tertiary lymphoid structures', TLSs)[24]. First, we checked whether T cells colocalized with CD20+ B cells, since both T and B cells are the main components of secondary lymphoid organs[25]. Indeed, in four immune-infiltrated pediatric AML BM samples, we detected large aggregates composed of T- and B cells ('lymphoid aggregates'; defined as networks of at least 100 directly interacting T cells that colocalized with a dense core of CD20+ B cells). Interestingly, all four patients had *KMT2A*-rearranged AML. Importantly, these lymphoid aggregates were not classified as malignant upon pathological examination[26]. In fact, these aggregates had a non-trabecular localization, did not contain cells with atypical morphology, and showed a predominance of CD3+ T cells, all features that have been associated with benign BM lymphoid aggregates[26].

In immune-depleted and non-leukemic control samples, we did not detect such lymphoid
aggregates. Moreover, in solid cancers, TLSs arise in the context of chronic inflammation[24],
which may also have driven the formation of lymphoid aggregates in the BM of immune-
infiltrated samples. To test whether lymphoid aggregates in the BM of pediatric AML patients
represent structures similar to TLSs, we performed spatial transcriptomics using the GeoMx
platform on bone biopsy tissue of two *KMT2A*-rearranged patients that had an immune-
infiltrated BM with lymphoid aggregates (**Fig. 4A-B**)[27]. As a control, we used tissue of one
*KMT2A*-rearranged patient with an immune-infiltrated BM but without these aggregates (**Fig.**
**4C**). In total, we successfully sequenced 94 regions: (1) regions that contained lymphoid
aggregates (n=20), (2) regions with T cell networks (n=26), and (3) regions that consisted of
a mixture of AML-, T-, and B cells ('mixed' regions; n=48). Then, we explored which regions
expressed TLS-associated genes using a previously generated TLS-signature (**Fig. 4A-C**)[28].
In general, we observed concordant enrichment of the TLS-signature in areas we designated
as regions containing lymphoid aggregates and hence, termed these structures 'TLS-like
aggregates' (**Fig. 4A-B**). Surprisingly, one region in the biopsy without lymphoid aggregates
was heavily enriched for the TLS-signature, possibly reflecting a forming or disintegrating TLS-
like aggregate (**Fig. 4C**).

We next used *SpatialDecon*, a deconvolution approach optimized for spatial
transcriptomic data, to examine the abundance of multiple immune and stromal cell types in
these TLS-like aggregates[29]. To this end, we used safeTME, a scRNA-seq and flow-sorted
bulk RNA-seq based reference profile of microenvironmental cell populations[29]. Importantly,
the similarity in cellular composition identified using unsupervised hierarchical clustering
(Euclidian distance; complete linkage) was highly concordant with our IHC-based distinction
between regions (**Fig. 5A**). Interestingly, TLS-like aggregate regions and T cell networks both
showed a significantly higher abundance of memory cytotoxic T cells, potentially because of
local cytotoxic T cell priming (**Fig. 5B**)[13]. However, both types of regions also had a
significantly higher abundance of Tregs, which may be a limiting factor of anti-tumor immunity
(**Fig. 5C**)[30]. Because of this colocalization of cytotoxic T cells with Tregs, we interrogated the
functional state of cytotoxic T cells using an additional scRNAseq reference profile specific for
activated and resting BM T cells[29]. TLS-like aggregate regions not only had a significantly
higher abundance of both activated and resting cytotoxic T cells, but also showed the highest
ratio of activated to resting cytotoxic T cells in comparison to T cell network- and mixed regions
(mean ratio of 0.72, 0.68, and 0.55, respectively), suggesting that cytotoxic T cells in TLS-like
aggregates are present in an activated state despite the presence of Tregs (**Fig. 5D-E** & **Fig.**
**S2B**). Furthermore, the relatively high number of activated T cells may explain the absence of
AML cells in these areas. In contrast to the T cell compartment, TLS-like aggregate regions

had a significantly higher abundance of all measured B cell populations in comparison to
mixed- and T cell network regions (**Fig. 5F-H**). Notably, differential gene expression analysis
between TLS-like aggregate and mixed regions showed upregulation of genes indicative of
immunoglobulin class-switching (*IGHG3*, *IGHG4*, *IGHA1*; **Fig. S2A**). Also, we confirmed the
enrichment of plasma and/or memory B cells in TLS-like aggregate regions using IHC,
together suggesting anti-tumor antibody production in TLS-like aggregate regions (**Fig. 5I**)[31].
Other critical components of the TLSs seen in solid cancers are dendritic cells because of their
pivotal role in priming of the immune response[24]. Interestingly, myeloid but not plasmacytoid
dendritic cells were significantly enriched in TLS-like aggregate regions in comparison to
mixed regions (**Fig. 5I** & **Fig. S2C**). Furthermore, macrophages were significantly enriched in
TLS-like aggregate and T cell network regions in comparison to mixed regions, which we
validated using IHC (**Fig. 5J&M**). Specifically, TLS-like aggregates and T cell network regions
showed a modest decrease in the abundance of M2-like macrophages compared to mixed
regions, suggesting that the M1-like macrophage abundance was increased in TLS-like
aggregate and T cell network regions (**Fig. 5K**). In contrast, neutrophils had a significantly
higher abundance in mixed regions (**Fig. S2D**).

Finally, since the presence of TLSs, with few exceptions, has been associated with
favorable prognosis and response to immunotherapy in solid cancers, we wondered whether
the presence of TLS-like aggregates was linked to outcome in patients with AML[24].
Unfortunately, the lack of access to pre-treatment RNA-sequencing data from immunotherapy-
treated AML patients precluded investigating whether the presence of TLS-like aggregates is
associated with immunotherapy response in AML. As the low number of patients with TLS-like
aggregates in our chemotherapy-treated cohort did not allow for robust outcome analyses, we
took advantage of publicly available bulk RNA-sequencing data from newly diagnosed
pediatric and adult AML patients and used the above-mentioned TLS-signature as a surrogate
for the presence of TLS-like aggregates. We found a trend towards improved overall survival
for adult AML but not for pediatric AML patients with a TLS-signature score above the median
($P = 0.075$ and $P = 0.53$, respectively; **Fig. S3A-B**; TARGET-AML cohort (n=145) and TCGA-
cohort (n=140), respectively)[28,32-33]. Collectively, these results suggest that *KMT2A*-
rearranged pediatric AML patients with an immune-infiltrated BM may harbor spatially
organized areas of cellular and humoral anti-tumor immunity in the BM, which may translate
to a positive effect on response upon T cell-engaging immunotherapies[24].

**Discussion**
Pediatric cancers are characterized by a relatively low mutational burden and therefore,
children are thought to be poor candidates for T cell-engaging immunotherapies[2,3]. This
prompted us to perform a multidimensional characterization of the tumor immune

microenvironment in newly diagnosed children with *de novo* AML and non-leukemic controls.
We identified a subset of patients with remarkably high T cell infiltration in the BM, dissected
the spatial organization of the immune compartment, and for the first time, unraveled the
composition of TLS-like aggregates in the BM of AML.

Despite the relatively low mutational burden and the associated poor immunogenicity
of pediatric cancers, previous work has shown that considerable variation in immune cell
infiltration exists in cancers that are considered to be immunologically 'cold'[4,6]. Indeed, we
observed wide variation in T cell infiltration in the BM of pediatric AML patients, including a
subset that had remarkably high levels of T cell infiltration. These immune-infiltrated samples
showed gene expression suggestive of an enrichment of GZMK[+] cytotoxic T cells, which has
been associated with response to immune checkpoint blockade in adult AML patients[11].
Hence, pediatric AML patients with an immune-infiltrated BM may show increased responses
to immune checkpoint inhibitors in comparison to patients with an immune-depleted BM.
Specifically, the immune checkpoint receptor genes *TIGIT* and *LAG3* were the most
upregulated immune checkpoint genes in immune-infiltrated patients, suggesting that these
less conventional checkpoint receptors may prove interesting immunotherapeutic targets in
pediatric AML[14,34]. Furthermore, we identified that immune-infiltrated samples harbored a
significantly lower abundance of the immunosuppressive M2-like macrophages in comparison
to immune-depleted samples. Therefore, repolarizing M2-like macrophages towards an M1-
like phenotype could be a suitable immunotherapeutic option in pediatric AML patients with
an immune-depleted BM[35]. Of interest, a recent study indicated that M2-like macrophages in
the BM of adult AML patients showed increased expression of the immune checkpoints TIGIT
and LAG-3 compared to healthy donors, and that TIGIT blockade was able to repolarize these
M2-like macrophages to an M1-like phenotype[36]. Thus, TIGIT and LAG-3 blockade may have
beneficial effects on both the T cell and macrophage compartment, which encourages further
evaluation of these agents in the preclinical setting.

In solid cancers, the importance of the spatial component of the immune response is
widely recognized. For instance, in the so-called 'excluded' tumors, an immune response is
triggered but not able to invade the tumor bed and hence, associates with poor response to
immunotherapy[1]. In hematological malignancies, the spatial organization of the immune
response is understudied, while potentially critical to the success of immunotherapeutic
interventions. In our study, we identified large aggregates of T- and B cells in the leukemic BM
that resembled gene expression characteristics of TLSs[28]. Importantly, pathology examination
indicated that the TLS-like aggregates detected in immune-infiltrated pediatric AML samples
in our cohort were not of malignant origin. In fact, these aggregates likely arose because of
the chronically inflamed tumor microenvironment, as seen with TLSs in solid cancers[24]. In line

with this, we did not detect TLS-like aggregates in the immune-depleted or non-leukemic
control samples. Furthermore, we dissected the composition of these TLS-like aggregates in
the BM of pediatric AML patients, which turned out to be local hotspots of activated cytotoxic
T cells, memory B cells, and plasma cells. Moreover, these hotspots were largely devoid of
AML cells despite full-blown leukemia in other areas of the BM. Hence, these data suggest
the presence of localized anti-tumor immunity in the BM of AML, which may have profound
implications for future immunotherapy approaches. For instance, the increased abundance of
plasma cells and the expression of class-switched immunoglobulin genes suggest the
production of anti-tumor antibodies, which may lead to novel targets for antibody-based
therapies through identification of the respective target antigens[37]. Likewise, the presence of
TLS-like aggregates in AML may pave the way for new adoptive cell therapies with tumor-
infiltrating T cells, since the T cells primed in these structures are likely to be tumor-reactive[24].
Current immunotherapies may also release the breaks of TLS-like aggregate-associated anti-
tumor immunity, as illustrated by the results of a recent clinical trial in advanced soft-tissue
sarcoma which showed that patients enrolled based on the presence of TLSs had an overall
response rate of 30% to PD-1 blockade, opposed to 2.4% in an unselected cohort[38].

Remarkably, all four patients with TLS-like aggregates in the BM had a *KMT2A*-
rearrangement. Although we detected wide variation in T cell infiltration in patients with this
cytogenetic alteration, the detection of these aggregates in patients with *KMT2A*-rearranged
AML indicates that at least some of these patients, which have relatively poor outcomes upon
chemotherapy, may be good candidates for immunotherapy. Furthermore, in an external
dataset of chemotherapy-treated adult AML patients, we identified that a high TLS-signature
score showed a trend towards better survival, while we did not identify such an association in
a large dataset of chemotherapy-treated pediatric AML patients. We speculate that this
discrepancy between adult and pediatric AML may be related to differences in the composition
of TLS-like aggregates, or to chemotherapy-induced remodeling of these structures, both
topics that demand further study[24]. Unfortunately, we did not have access to pre-treatment
bone biopsies or RNA-sequencing data from AML patients treated with T cell-engaging
immunotherapies and therefore, it was not possible to study the predictive effect of TLS-like
aggregates in this context. However, the predictive effect of these structures may easily be
studied in both retrospective and future immunotherapy studies. In conclusion, our results
suggest the presence of distinct immune phenotypes in the BM of patients with pediatric AML
including the presence of TLS-like aggregates in *KMT2A*-rearranged AML, suggesting that a
subset of children with AML may benefit from T cell-engaging immunotherapies, and which
encourages further study of these lymphoid structures in the BM in the context of
immunotherapy in AML.

## Methods

### Ethical regulation

This study complies with all relevant ethical regulations and was approved by the Institutional Review Board of the Princess Máxima Center for Pediatric Oncology (PMCLAB2021.207 & PMCLAB2021.238) and the Scientific Committee of the Dutch Nationwide Pathology Databank (PALGA: lzv2021-82)[39]. All patients treated at the Princess Máxima Center provided written consent for banking and research use of these specimens, according to the Declaration of Helsinki. Bone biopsy tissues acquired from external biobanks (n=28) were leftover material from standard care procedures and therefore, no informed consent was acquired, according to Dutch legislation and the code of conduct of the Committee on Regulation of Health Research (COREON).

### Human patient samples

FFPE bone biopsies taken from the crista of children with treatment-naïve *de novo* AML were obtained from the Princess Máxima Center Biobank (n=15) and biobanks of 10 other Dutch hospitals (n=28), mediated by the Dutch National Tissue Portal. As controls, FFPE bone biopsies of age- and sex-matched children with treatment-naïve early-stage rhabdomyosarcoma were obtained from the Princess Máxima Center Biobank (n=10; non-leukemic controls). An experienced hemato-onco pathologist confirmed that these control biopsies resembled normal hematopoiesis and that there was no malignancy infiltrating the BM.

### Immunohistochemistry staining and digital image analysis

Bone biopsies were cut into consecutive 4 µm sections and stained with hematoxylin and eosin (H&E). Conventional IHC was performed for CD3, CD3-CD4 (duplex), CD8, CD20, CD34, CD117, CD15, and IgM-IgG (duplex) using a Ventana Benchmark Ultra (Roche, Basel, Switzerland) automated staining instrument according to manufacturers' recommendations. A list of antibodies and suppliers is available in **Table S3**. Digital scans of stained slides were obtained using a NanoZoomer scanner (Hamamatsu, Shizuoka, Japan). On 4 µm sections from three *KMT2A*-rearranged pediatric AML patients with an immune-infiltrated BM, we applied the FixVUE APC™ Kit (Ultivue Inc. Cambridge, MA, USA; CD20, CD68/CD163 cocktail, CD11c, and MHC-II) using the antibody conjugated DNA-barcoded multiplexed immunofluorescence method, as previously described[40]. The staining was performed on the BOND RX (Leica Biosystems, Wetzlar, Germany). To acquire an H&E staining on the same slide, the fluorescently labelled slides were soaked in PBS until the coverslips could be removed, and a standard H&E stain was performed using an Epredia Gemini (Epredia,

Portsmouth, UK). Digital immunofluorescence and brightfield images were scanned on a Zeiss
Axioscan Z1 (ZEISS, Oberkochen, Germany) and stacked with Ultivue's UltiStacker software.
Whole-slide digital image analysis was performed in QuPath (V.0.3.2)[41]. Inside QuPath, the
deep learning-based cell segmentation tool StarDist and the machine learning-based Random
Trees classifier were used to quantify the number of positive cells per mm$^2$ [42]. T cell networks
were defined as at least 10 directly interacting CD3$^+$ T cells (≤ 10 μm between adjacent nuclei),
detected using Delaunay Triangulation, and normalized per 10 cm$^2$ [42-43]. Large T cell networks
of at least 100 directly interacting T cells that colocalized with a dense core of CD20$^+$ B cells
were classified as lymphoid aggregates.

**Immune-related gene expression profiling**

Four consecutive sections of 10 μm from 5 immune-infiltrated and 18 immune-depleted FFPE
bone biopsies (the non-leukemic controls' median value of cytotoxic T cells was used as the
cut-off value) from a cytogenetically representative cohort of pediatric AML patients were used
to isolate RNA and to perform immune-related gene expression profiling with the 770-gene
PanCancer IO 360 panel, as previously described (NanoString, Seattle, WA, USA)[19,44]. After
passing quality control, raw data were normalized using ROSALIND® according to
Nanostring's recommendations (https://rosalind.bio/; San Diego, CA, USA). Normalized data
were uploaded to the online iDEP platform and differentially expressed genes between
immune-infiltrated and immune-depleted samples were identified using *DEseq2* with a false-
discovery rate (FDR) cut-off of 0.05 and a minimum fold change of 2 (integrative Differential
Expression and Pathway analysis; http://bioinformatics.sdstate.edu/idep96/; V.0.96)[45].
Pathway analysis was performed using parametric gene set enrichment analysis with the GO
Biological Processes gene set with an FDR of 0.05[46,47]. The abundance of M2-like
macrophages was estimated using a published gene signature of M2-like macrophages
compared to M1-like macrophages, inside the TIDE environment (tide.dfci.harvard.edu/)[17,48].
Similarly, the T cell inflamed gene expression profile, the CD8-, IFN-$\gamma$-, and TIDE scores were
all calculated using TIDE.

**GeoMx Digital Spatial Profiling**

5 μm thick FFPE bone biopsy sections from three *KMT2A*-rearranged pediatric AML patients
with an immune-infiltrated BM were placed on the same slide and prepared for GeoMx Digital
Spatial Profiling (DSP; NanoString), as previously described[27]. Slides were simultaneously
incubated with immunofluorescent antibodies and GeoMx Whole Transcriptome Atlas profiling
reagents. SYTO13 (S7575, Thermo Fisher,) was used for identification of nuclei, CD45
(NBP2-34528, Novus) for leukocytes, and CD3 (NBP2-54392AF647, Novus) for T cells.
Stained slides were loaded onto the GeoMx instrument and scanned. Regions of interest

(ROIs) were selected using the above-mentioned antibodies in combination with overlayed
images of CD20, CD34, CD3-CD4 (duplex), and CD117 (IHC). Then, UV-photocleaved
oligonucleotides were collected in separate wells and sequenced on the Nextseq2000
(Illumina, San Diego, CA, USA). In total, we successfully sequenced 94 regions (one failed
quality control) with on average 273 cells per region (range: 156 to 778 cells). Raw data were
normalized using Quartile 3 count (Q3) normalization in R (V.4.2.1) as per NanoString's
recommendations (code is available in the vignette of the *Geomxtools* package). The
expression of the TLS-signature as described by Meylan et al. was plotted in R on the scanned
image using *SpatialOmicsOverlay*[28]. Spatial Deconvolution was performed in the GeoMx DSP
Analysis Suite using both the safeTME and healthy adult BM T cell reference profiles
(*SpatialDecon* package; cell reference profiles are available via https://github.com/Nanostring-
Biostats/CellProfileLibrary)[29]. Differential gene expression analysis between regions was
performed using a linear mixed-effects model including random slope to correct for the fact
that multiple regions come from the same biopsy, and the FDR method (code: *Geomxtools*
package; minimum fold change of 2).

**External pediatric and adult AML datasets**

Single-cell RNA-sequencing (scRNAseq) data from 8 newly diagnosed pediatric AML patients
were re-analyzed for cell-type specific *PDCD1*, *CTLA4*, *TIGIT*, and *LAG3* expression using
the Tumor Immune Single-cell Hub[14,49]. Immune-related gene expression data (PanCancer IO
360 panel) from pre-treatment BM samples from 30 relapsed or refractory adult AML patients
that were treated with flotetuzumab in the context of the CP-MGD006-01 clinical trial
(NCT02152956) were kindly provided by Professor Sergio Rutella (Nottingham Trent
University, England) and dr. Patrick Kaminker (MacroGenics, Rockville, MD, USA) and
analyzed as described above. The association between the TLS-signature score[28] (averaged
expression of normalized counts) and overall survival of 145 and 140 newly diagnosed *de*
*novo* pediatric and adult AML patients was evaluated using the online platform SurvivalGenie,
respectively (TARGET-AML and TCGA-AML cohorts;
https://bbisr.shinyapps.winship.emory.edu/SurvivalGenie/)[32-33,50].

**Statistical analyses**

Statistical analyses were performed with GraphPad Prism V.9.3.0 (GraphPad Software, LA
Jolla, CA, USA). Time to event analyses were performed with SurvivalGenie[50]. Differences
between two independent groups were compared using the Mann-Whitney test. The
correlation between two variables was evaluated using Spearman's *r*. To measure the area
under the receiver operating characteristic curve, we employed the Wilson-Brown method. To
estimate the survival from diagnosis, the Kaplan-Meier's methodology was employed. To

assess the difference between survival estimates in different groups, the log rank test was
used. In case of multiple comparisons and no Gaussian distribution of residuals, we employed
the Kruskal-Wallis test followed by Dunn's test for multiple comparisons including a Bonferroni
correction. Hence for the multiple testing, $P<0.01$ was considered statistically significant in
these comparisons. For all the other comparisons, $P<0.05$ was considered statistically
significant.

### Data availability

447  Sequencing data can be accessed from the Gene Expression Omnibus (nCounter data:
448  GSEXXX; GeoMx data: GSEXXX; both normalized counts [GSE IDs will be available upon
449  approval]) and from the European Genome-phenome Archive (EGA) database (https://ega-
450  archive.org/studies/EGAXXX; raw nCounter and GeoMx data [idem]).

### Acknowledgements

We would like to thank the staff of the University Medical Center Utrecht Tissue Facility for
their excellent immunohistochemistry service (Domenico Castigliego, Petra van der Weide,
Petra van der Kraak, Karina Timmer, Sven van Kempen), and the team at Utrecht Sequencing
Facility for performing the NanoString experiments (nCounter and GeoMx) and for providing
assistance with data-analysis (dr. Ies Nijman, Robin Geene, Pim Kloosterman). We are
grateful to Professor Sergio Rutella (Notthingham Trent University) and dr. Patrick Kaminker
(MacroGenics) for providing us with immune-related gene expression data from
immunotherapy-treated adult AML samples. Dr. Ivette Deckers and dr. Annette Gijsbers
(PALGA) performed essential work for the acquisition of bone biopsies from other hospitals.
From the Princess Máxima Center for Pediatric Oncology, prof. dr. Gertjan Kaspers and dr.
Bianca Goemans aided with identifying potential patients, the biobank staff (Jantien Woudstra,
Marion Koopmans, dr. Edwin Sonneveld) helped to identify patient material, and Arie Maat
aided with the sectioning of bone biopsy sections. Also, we would like to thank dr. Caroline
Lindemans, members from the Heidenreich group (dr. Katarzyna Szoltysek, dr. Farnaz
Barneh, dr. Mauricio Ferrao-Blanco, Elizabeth Schweighart, Nina van der Wilt), the Van
Heesch group (dr. Ana Pinheiro-Lopes), and the single-cell sequencing facility (dr. Lindy
Visser) at the Princess Máxima Center for Pediatric Oncology for carefully reading the
manuscript and/or fruitful discussions. This work has been funded in part by a KIKA (329)
program grant to O.H. Figure 1A and 3A have been created using BioRender.com.

### Author contributions

472  Conceptualization: J.B.K, I.W., M.A.V., S.N., M.B., C.M.Z., O.H. Methodology: J.B.K, I.W.,
473  M.A.V., M.F., S.N., M.B., C.M.Z., O.H. Data acquisition: J.B.K., M.A.V., H.G.-K., R.M. Data

474    analysis and interpretation: J.B.K., I.W., A.P. Writing – Original Draft: J.B.K.; Writing –

475    Reviewing & Editing: all authors; Supervision: S.N., M.B., C.M.Z., O.H.

**References**

1. Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. *Nat Rev Cancer*. 2020;20(11):662-680.
2. Majzner RG, Heitzeneder S, Mackall CL. Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. *Cancer Cell*. 2017;31(4):476-485.
3. Pfister SM, Reyes-Múgica M, Chan JKC, Hasle H, Lazar AJ, Rossi S, et al. A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. *Cancer Discov*. 2022;12(2):331-355.
4. Dufva O, Pölönen P, Brück O, Keränen MAI, Klievink J, Mehtonen J, et al. Immunogenomic Landscape of Hematological Malignancies. *Cancer Cell*. 2020;38(3):380-399.e13.
5. Serroukh Y, Hébert J, Busque L, Mercier F, Rudd CE, Assouline S, et al. Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. *Blood Rev*. 2023;57:100991.
6. Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. *Nature*. 2018;555(7696):321-327.
7. Vadakekolathu J, Lai C, Reeder S, Church SE, Hood T, Lourdusamy A, et al. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. *Blood Adv*. 2020;4(20):5011-5024.
8. Koedijk JB, van der Werf I, Calkoen FG, Nierkens S, Kaspers GJL, Zwaan CM, et al. Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward. *Cancers (Basel)*. 2021;13(17):4364.
9. Wellenstein MD, de Visser KE. Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. *Immunity*. 2018;48(3):399-416.
10. de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: From Biology to Clinical Management. *J Clin Med*. 2015;4(1):127-149.
11. Abbas HA, Hao D, Tomczak K, Barrodia P, Seon Im J, Reville PK, et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. *Nat Commun*. 2021;12(1):6071.
12. Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. *Clin Cancer Res*. 2014;20(1):44-55.
13. Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. *Nat Rev Immunol*. 2022;22(4):209-223.
14. Bailur JK, McCachren SS, Pendleton K, Vasquez JC, Seo Lim H, Duffy A, et al. Risk-associated alterations in marrow T cells in pediatric leukemia. *JCI Insight*. 2020;5(16):e140179.
15. House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, et al. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. *Clin Cancer Res*. 2020;26(2):487-504.
16. Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation. *Front Immunol*. 2014;5:514.
17. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. *Nat Med*. 2018;24(10):1550-1558.

18. Mussai F, De Santo C, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM, et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. *Blood*. 2013;122(5):749-758.

19. Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. *Sci Transl Med*. 2020;12(546):eaaz0463.

20. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. *J Clin Invest*. 2017;127(8):2930-2940.

21. Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M, et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. *Nat Med*. 2003;9(9):1151-1157.

22. Gaglia G, Burger M, Ritch CC, Rammos D, Dai Y, Crossland GE, et al. Lymphocyte networks are dynamic communities in the immunoregulatory landscape of lung adenocarcinoma. *bioRxiv*. 2022-08.

23. Pospori C, Grey W, Gonzalez Anton S, Gibson S, Georgiou C, Birch F, et al. Dynamic regulation of hierarchical heterogeneity in acute myeloid leukemia serves as a tumor immunoevasion mechanism. bioRxiv. 2020-12.

24. Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. *Science*. 2022;375(6576):eabf9419.

25. Ruddle NH, Akirav EM. Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response. *J Immunol*. 2009;183(4):2205-2212.

26. Maccio U, Rets AV. Lymphoid aggregates in bone marrow: a diagnostic pitfall. *J Clin Pathol*. 2022;75(12):807-814.

27. Merritt CR, Ong GT, Church SE, Barker K, Danaher P, Geiss G, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. *Nat Biotechnol*. 2020;38(5):586-599.

28. Meylan M, Petitprez F, Becht E, Bougoüin A, Pupier G, Calvez A, et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. *Immunity*. S2022;55(3):527-541.e5.

29. Danaher P, Kim Y, Nelson B, Griswold M, Yang Z, Piazza E, et al. Advances in mixed cell deconvolution enable quantification of cell types in spatial transcriptomic data. *Nat Commun*. 2022;13(1):385

30. Joshi NS, Akama-Garren EH, Lu Y, Lee D-Y, Chang GP, Li A, et al. Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. *Immunity*. 2015;43(3):579-590.

31. Akkaya M, Kwak K, Pierce SK. B cell memory: building two walls of protection against pathogens. *Nat Rev Immunol*. 2020;20(4):229-238.

32. Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. *Nat Med*. 2018;24(1):103-112.

33. Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*. 2013;368(22):2059-2074.

34. Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. *Nat Cancer*. 2023;4(1):27-42.

35. Li W, Wang F, Guo R, Bian Z, Song Y. Targeting macrophages in hematological malignancies: recent advances and future directions. *J Hematol Oncol.* 2022;15(1):110.

36. Brauneck F, Fischer B, Witt M, Muschhammer J, Oelrich J, Henrique da Costa Avelar P, et al. TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis. *J Immunother Cancer.* 2022;10(12):e004794.

37. Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Sautès-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. *Nat Rev Clin Oncol.* 2022;19(7):441-457.

38. Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. *Nat Med.* 2022;28(6):1199-1206.

39. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JHJM, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. *Cell Oncol.* 2007;29(1):19-24.

40. Manesse M, Patel KK, Bobrow M, Downing SR. The InSituPlex® Staining Method for Multiplexed Immunofluorescence Cell Phenotyping and Spatial Profiling of Tumor FFPE Samples. *Methods Mol Biol.* 2020;2055:585-592.

41. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. *Sci Rep.* 2017;7(1):16878.

42. Schmidt U, Weigert M, Broaddus C, Myers G. Cell detection with star-convex polygons. *International Conference on Medical Image Computing and Computer-Assisted Intervention.* 2018;265-273.

43. Delaunay B. Sur la sphère vide. *Bull. Acad. Sci. URSS.* 1934:793–800.

44. Danaher P, Warren S, Dennis L, D'Amico L, White A, Disis ML, et al. Gene expression markers of Tumor Infiltrating Leukocytes. *J Immunother Cancer.* 2017;5:18.

45. Ge SX, Son EW, Yao R. iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. *BMC Bioinformatics.* 2018;19(1):534.

46. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet.* 2000;25(1):25-29.

47. Gene Ontology Consortium. The Gene Ontology resource: enriching a GOld mine. *Nucleic Acids Res.* 2021;49(D1):D325-D334.

48. Beyer M, Mallmann MR, Xue J, Staratcheck-Jox A, Vorholt D, Krebs W, et al. High-resolution transcriptome of human macrophages. *PLoS One.* 2012;7(9):e45466.

49. Sun D, Wang J, Han Y, Dong X, Ge J, Zheng R, et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. *Nucleic Acids Res.* 2021;49(D1):D1420-D1430.

50. Dwivedi B, Mumme H, Satpathy S, Bhasin SS, Bhasin M. Survival Genie, a web platform for survival analysis across pediatric and adult cancers. *Sci Rep.* 2022;12(1):3069

**Figure Legends**

**Figure 1. Spatial analysis of the bone marrow immune microenvironment in pediatric AML and non-leukemic controls.**

(A) Schematic overview of the study population, used techniques, and the digital image analysis pipeline. (B-C) Representative bone biopsy images acquired from a treatment-naïve pediatric AML patient (B) and non-leukemic control (C) showing H&E staining, CD3$^+$ T cells (CD3 in brown), and CD8$^+$ T cells (CD8 in brown). White lobules indicate adipocytes. (D-E) Comparison of the normalized abundance of CD3$^+$ T cells (D) and CD8$^+$ T cells (E) in the BM between pediatric AML patients and non-leukemic controls. (F-G) Normalized abundance of CD3$^+$ T cells (F) and CD8$^+$ T cells (G) per cytogenetic pediatric AML subgroup. 'Normal' indicates normal karyotype, while 'Others' is a merge of cytogenetic abnormalities different from the four defined cytogenetic subgroups.

**Figure 2. Transcriptional differences between immune-infiltrated and immune-depleted pediatric AML samples.**

(A) Volcano plot of differentially expressed genes between immune-infiltrated and immune-depleted pediatric AML BM samples, identified using *DEseq2* with an FDR cut-off of 0.05 and minimum fold change (FC) of 2. (B) Parametric gene set enrichment analysis of differentially expressed genes between immune-infiltrated (orange) and immune-depleted samples (blue) using the GO Biological Processes gene set with an FDR cut-off of 0.05. Values in front of the biological processes indicate *P* values. (C) Correlation plot of the inverse correlation between the M2-like macrophage abundance and the normalized number of CD3$^+$ T cells, calculated using Spearman correlation. (D-E) Comparison of the M2-like macrophage abundance between immune-infiltrated (n=5) and immune-depleted (n=18) BM samples (D) and between BM samples of refractory or relapsed (R/R) adult AML patients with anti-leukemic activity (ALA) or non-responders (NR) to treatment with the bispecific antibody flotetuzumab (E). (F) Area under the receiver operating characteristic curves measuring the predictive ability of the M2-like macrophage abundance (black), T cell inflamed gene expression profile (GEP; pink), CD8 score (blue), IFN-γ score (green), and the tumor immune dysfunction and exclusion score (TIDE; orange) in pre-treatment R/R adult AML samples for response to flotetuzumab.

**Figure 3. Immune-infiltrated pediatric AML samples harbor an increased abundance of spatially organized T cell networks.**

(A) Illustration of the identification of directly interacting T cells (above) and T cell networks (below) using Delaunay Triangulation. (B) Comparison of the normalized abundance of T cell

networks between immune-infiltrated, immune-depleted, and non-leukemic control samples.

(C) Correlation plot of the positive correlation between the normalized number of CD3[+] T

cells and the normalized number of T cell networks in both AML and non-leukemic control

samples (n=53), calculated using Spearman correlation. (D) Comparison of the number of T

cell networks with at least 100 T cells/network between immune-infiltrated, immune-

depleted, and non-leukemic control samples. (E-F) Representative images of an immune-

infiltrated pediatric AML BM sample with multiple large T cell clusters (>100 T cells; CD3 in

brown; E) that are largely devoid of AML cells (CD117 in brown, patient-specific AML

immunophenotypic marker; F). (G-H). Representative images of an immune-depleted

pediatric AML BM sample without T cell clusters (CD3 in brown; G) and widely dispersed

AML cells (CD117 in brown; patient-specific AML immunophenotypic marker; H).

**Figure 4. Spatial transcriptomics reveals gene expression characteristics of tertiary**

**lymphoid structures in *KMT2A*-rearranged immune-infiltrated pediatric AML samples.**

(A-C) Images of the bone biopsy sections that show the expression levels of a previously

published TLS-signature in distinct regions of two lymphoid aggregate (LA)-positive (A+B)

*KMT2A*-rearranged immune-infiltrated pediatric AML samples and one LA-negative (C)

*KMT2A*-rearranged immune-infiltrated pediatric AML sample, next to immunohistochemistry-

based images of CD3[+] T cells, CD20[+] B cells, and CD117[+] (A+C) or CD4[+] (B) AML cells.

Orange arrows indicate LA-containing regions.

**Figure 5. Spatial deconvolution identifies localized cellular and humoral immunity in**

***KMT2A*-rearranged immune-infiltrated pediatric AML samples.**

(A) Dendrogram and bar plot of absolute immune- and stromal-cell abundance scores,

calculated by applying the *SpatialDecon* algorithm to spatial transcriptomic data from three

*KMT2A*-rearranged immune-infiltrated pediatric AML BM samples. Regions are divided in

separate clusters based on similarity (unsupervised hierarchical clustering; Euclidian

distance; complete linkage). The legend on the right indicates which type of cell is shown in

the bar plot and for which type of region the cell composition is shown. (B-K) Comparisons of

the abundance scores of several immune- and stromal cell types between mixed regions

(n=48), T cell network regions (n=26), and TLS-like aggregate regions (n=20). Tregs

indicates regulatory T cells, and DCs indicate dendritic cells. (I) Whole-slide bone biopsy

image with a CD3 stain (brown) for T cells (above), and a magnified image illustrating the

presence of IgM[+]- (brown) and IgG[+]-cells (purple) in the T cell rich area that is part of an

TLS-like aggregate. (M) Magnifications of the T cell rich area shown in the whole-slide image

shown in Figure I, showing the presence of CD11c[+] CD68/CD163[+] macrophages (red

arrows) in the TLS-like aggregate region.

# SUPPLEMENTARY INFORMATION

Spatial analysis reveals distinct immune phenotypes and tertiary lymphoid structure-like aggregates in pediatric acute myeloid leukemia

Joost B. Koedijk[1,2], Inge van der Werf[1,3], Marijn A. Vermeulen[1], Alicia Perzolli[1,2], Marta Fiocco[1,4,5], Hester A. de Groot-Kruseman[1], Rubina Moeniralam[1], Stefan Nierkens[1,6], Mirjam E. Belderbos[1], C. Michel Zwaan[1,2#], Olaf Heidenreich[1,7#*]

**Supplementary Table 1.** Patient characteristics from 43 treatment-naïve pediatric patients with AML and 10 treatment-naïve non-leukemic controls.

| ID | Sex | %BM Myelo-blasts | FAB | Cytogenetic alterations | Molecular aberrations | Immune infiltration | GEP + Spatial Tx |
|---|---|---|---|---|---|---|---|
| AML1 | male | 32 | M2 | NA | NA | Infiltrated | GEP |
| AML2 | female | 51 | M5 | KMT2Ar | none | Infiltrated | GEP + Spatial Tx |
| AML3 | male | NA | NA | KMT2Ar | none | Infiltrated | GEP |
| AML4 | male | 55 | NA | KMT2Ar | none | Infiltrated | GEP |
| AML5 | male | 28 | NA | KMT2Ar, Trisomy-8 | none | Infiltrated | Spatial Tx |
| AML6 | male | 44 | NA | KMT2Ar | none | Infiltrated | GEP + Spatial Tx |
| AML7 | male | 39 | NA | inv(16) | none | Infiltrated | |
| AML8 | male | 81 | NA | t(8;21), 8q-deletion, Y-chromosome deletion | EXT1mut + RAD21mut | Infiltrated | |
| AML9 | male | 63 | NA | KMT2Ar | none | Depleted | |
| AML10 | male | 81 | NA | KMT2Ar | none | Depleted | |
| AML11 | male | 73 | M5 | inv(16) | none | Depleted | |
| AML12 | male | 77 | M2 | t(8;21) | none | Depleted | GEP |

| AML13 | female | NA | NA | Normal karyotype | NPM1mut + WT-1mut | Depleted | GEP |
|-------|--------|-----|-----|------------------|-------------------|----------|-----|
| AML14 | male | 50 | M2 | t(8;21) | none | Depleted | |
| AML15 | female | 14 | M6 | NA | NA | Depleted | |
| AML16 | male | 88 | M1 | t(8;21) | none | Depleted | GEP |
| AML17 | female | 31 | M0 | Normal karyotype | none | Depleted | |
| AML18 | male | 10 | M7 | NA | NA | Depleted | |
| AML19 | male | NA | M5 | NA | NA | Depleted | |
| AML20 | female | NA | M6 | NA | NA | Depleted | |
| AML21 | female | 72 | M4 | Monosomy-7 | none | Depleted | GEP |
| AML22 | male | 94 | M5 | KMT2Ar | none | Depleted | GEP |
| AML23 | male | 98 | M5 | KMT2Ar | none | Depleted | GEP |
| AML24 | female | 20 | NA | NA | NA | Depleted | GEP |
| AML25 | male | 8 | M7 | Trisomy-8 | none | Depleted | GEP |
| AML26 | male | 80 | M5 | KMT2Ar | none | Depleted | GEP |
| AML27 | male | 36 | M2 | t(8;21) | WT-1mut | Depleted | GEP |
| AML28 | female | 69 | NA | KMT2Ar | none | Depleted | GEP |
| AML29 | male | 45 | M2 | NA | NA | Depleted | GEP |
| AML30 | male | 39 | M2 | NA | NA | Depleted | GEP |
| AML31 | female | NA | NA | NA | NA | Depleted | |
| AML32 | female | 38 | NA | inv(16) | none | Depleted | GEP |
| AML33 | female | 34 | NA | Normal karyotype | NPM1mut | Depleted | GEP |
| AML34 | male | NA | NA | Normal karyotype | FLT3-ITDmut | Depleted | GEP |
| AML35 | male | 92 | M5 | KMT2Ar | none | Depleted | |
| AML36 | female | 90 | M5 | KMT2Ar | none | Depleted | |
| AML37 | male | 32 | NA | 9q-deletion | none | Depleted | |
| AML38 | male | 18 | NA | Normal karyotype | none | Depleted | |
| AML39 | male | 0 | NA | Normal karyotype | NPM1mut | Depleted | |

| AML40 | male | 12 | NA | t(6;9) | WT1mut + NRASmut | Depleted | |
| AML41 | female | 5 | NA | t(5;11) | none | Depleted | |
| AML42 | male | 63 | NA | Monosomy-7, gain chromosome -13 | TP53mut, RUNX1mut, SUZ12mut | Depleted | GEP |
| AML43 | male | 92 | M5 | KMT2Ar | NRASmut | Depleted | GEP |
| CTRL1 | male | 1 | Not applicable | | | | |
| CTRL2 | female | 0 | Not applicable | | | | |
| CTRL3 | female | 1 | Not applicable | | | | |
| CTRL4 | male | 2 | Not applicable | | | | |
| CTRL5 | female | 3 | Not applicable | | | | |
| CTRL6 | male | 1 | Not applicable | | | | |
| CTRL7 | male | 1 | Not applicable | | | | |
| CTRL8 | male | 0 | Not applicable | | | | |
| CTRL9 | male | 2 | Not applicable | | | | |
| CTRL1 0 | female | 1 | Not applicable | | | | |

AML: acute myeloid leukemia; BM: bone marrow; CTRL: non-leukemic control; dx: diagnosis; FAB: French-American-British (classification); GEP: gene expression profiling; KMT2Ar: KMT2A-rearranged; mut: mutation; NA: not available; Spatial Tx: spatial transcriptomics.

**Supplementary Table 2.** Number of T cell networks and TLS-like aggregates for each patient.

| | | T cell network number (by size) | | | | |
| ID | Immune infiltration | 10-30 cells | 31-99 cells | 100-500 cells | >500 cells | TLS-like aggregates |
|---|---|---|---|---|---|---|
| AML1 | Infiltrated | 161 | 30 | 11 | 1 | NA |
| AML2 | Infiltrated | 191 | 57 | 15 | 8 | 6 |
| AML3 | Infiltrated | 473 | 62 | 11 | 0 | 11 |
| AML4 | Infiltrated | 92 | 11 | 1 | 0 | 1 |
| AML5 | Infiltrated | 22 | 1 | 0 | 0 | 0 |
| AML6 | Infiltrated | 320 | 48 | 7 | 1 | 4 |
| AML7 | Infiltrated | 138 | 2 | 0 | 0 | 0 |
| AML8 | Infiltrated | 18 | 0 | 0 | 0 | 0 |
| AML9 | Depleted | 541 | 61 | 0 | 0 | 0 |
| AML10 | Depleted | 242 | 9 | 0 | 0 | 0 |
| AML11 | Depleted | 0 | 0 | 0 | 0 | 0 |

| | | | | | | |
|---|---|---|---|---|---|---|
| AML12 | Depleted | 0 | 0 | 0 | 0 | 0 |
| AML13 | Depleted | 1 | 1 | 0 | 0 | 0 |
| AML14 | Depleted | 0 | 0 | 0 | 0 | 0 |
| AML15 | Depleted | 5 | 0 | 0 | 0 | 0 |
| AML16 | Depleted | 3 | 0 | 0 | 0 | 0 |
| AML17 | Depleted | 3 | 0 | 0 | 0 | 0 |
| AML18 | Depleted | 1 | 0 | 0 | 0 | 0 |
| AML19 | Depleted | 0 | 0 | 0 | 0 | 0 |
| AML20 | Depleted | 3 | 0 | 0 | 0 | 0 |
| AML21 | Depleted | 0 | 0 | 0 | 0 | 0 |
| AML22 | Depleted | 6 | 0 | 0 | 0 | 0 |
| AML23 | Depleted | 29 | 0 | 0 | 0 | 0 |
| AML24 | Depleted | 82 | 4 | 1 | 0 | NA |
| AML25 | Depleted | 4 | 0 | 0 | 0 | 0 |
| AML26 | Depleted | 1 | 0 | 0 | 0 | 0 |
| AML27 | Depleted | 1 | 0 | 0 | 0 | 0 |
| AML28 | Depleted | 30 | 0 | 0 | 0 | 0 |
| AML29 | Depleted | 8 | 1 | 0 | 0 | 0 |
| AML30 | Depleted | 10 | 0 | 1 | 0 | 1 |
| AML31 | Depleted | 6 | 0 | 0 | 0 | 0 |
| AML32 | Depleted | 0 | 0 | 0 | 0 | 0 |
| AML33 | Depleted | 0 | 0 | 0 | 0 | 0 |
| AML34 | Depleted | 7 | 0 | 0 | 0 | 0 |
| AML35 | Depleted | 27 | 1 | 0 | 0 | 0 |
| AML36 | Depleted | 0 | 0 | 0 | 0 | 0 |
| AML37 | Depleted | 2 | 1 | 0 | 0 | 0 |
| AML38 | Depleted | 0 | 0 | 0 | 0 | 0 |
| AML39 | Depleted | 19 | 1 | 0 | 0 | 0 |
| AML40 | Depleted | 5 | 0 | 0 | 0 | 0 |
| AML41 | Depleted | 51 | 7 | 0 | 0 | 0 |
| AML42 | Depleted | 58 | 3 | 0 | 0 | 0 |
| AML43 | Depleted | 74 | 7 | 1 | 0 | NA |
| CTRL1 | Control | 11 | 0 | 0 | 0 | 0 |
| CTRL2 | Control | 3 | 0 | 0 | 0 | 0 |
| CTRL3 | Control | 8 | 0 | 0 | 0 | 0 |
| CTRL4 | Control | 88 | 5 | 0 | 0 | 0 |
| CTRL5 | Control | 62 | 5 | 0 | 0 | 0 |
| CTRL6 | Control | 29 | 5 | 0 | 0 | 0 |
| CTRL7 | Control | 63 | 0 | 0 | 0 | 0 |
| CTRL8 | Control | 19 | 0 | 0 | 0 | 0 |
| CTRL9 | Control | 46 | 1 | 0 | 0 | 0 |
| CTRL10 | Control | 34 | 3 | 0 | 0 | 0 |

704 AML: acute myeloid leukemia; CTRL: non-leukemic control; TLS: tertiary lymphoid structure;
705 NA: the presence of TLS-like aggregates could not be assessed in these biopsies since a
706 CD20+ B cell stain was lacking.

Koedijk et al.

 **Supplementary Table 3.** Antibodies used for immunohistochemistry of bone biopsy tissue.

| Antibody | Code | Supplier | Catalog No. | Dilution |
|----------|------|----------|-------------|----------|
| CD3 | 2GV6 | Roche | 05278422001 | NA |
| CD4 | SP35 | Roche | 05552737001 | NA |
| CD8 | SP57 | Roche | 5973248001 | NA |
| CD20 | L26 | Roche | 5267099001 | NA |
| CD15 | MMA | Roche | 5266904001 | NA |
| CD34 | QBEnd/10 | Roche | 6389320001 | NA |
| CD117 | EP10 | Roche | 790-7061 | NA |
| IgM | GA513 | Dako | GA51361-2 | 1:24.000 |
| IgG | GA512 | Dako | GA51261-2 | 1:60.000 |

712 NA: Not applicable.

# Figure 1

# Figure 2

# Figure 3

**A** Direct contact
≤ 10 μm
T cell network
≥ 10 T cells in direct contact

**B** Kruskal-Wallis, *P* < 0.001
T cell networks / 10 cm²
< 0.001
Infiltrated (N=8)  Depleted (N=35)  Controls (N=10)

**C** *r* = 0.86
*P* < 0.001
T cell networks / 10 cm²
CD3+ cells/mm²

**D** Kruskal-Wallis, *P* < 0.001
T cell networks ≥ 100 T cells / 10 cm²
< 0.001
< 0.001
Infiltrated (N=8)  Depleted (N=27)  Controls (N=10)

**E** Immune-Infiltrated sample
600 μm
CD3

**F** 600 μm
CD117

**G** Immune-depleted sample
600 μm
CD3

**H** 600 μm
CD117

# Figure 4

# Figure 5

**A**

Abundance scores

Cell
- fibroblasts
- endothelial.cells
- Treg
- neutrophils
- monocytes.NC.I
- monocytes.C
- mDCs
- pDCs
- NK
- T.CD8.memory
- T.CD8.naive
- T.CD4.memory
- T.CD4.naive
- plasma
- B.memory
- B.naive
- mast
- macrophages

Annotation
- mixed
- T cell network
- TLS-like aggregate

**B** Memory cytotoxic T cells — Kruskal-Wallis, $P < 0.001$; $< 0.001$; $< 0.001$ — Mixed, T cell network, TLS-like

**C** Tregs — Kruskal-Wallis, $P < 0.001$; $< 0.001$; $< 0.001$ — Mixed, T cell network, TLS-like

**D** Activated CD8+ T cells — Kruskal-Wallis, $P < 0.001$; $< 0.001$; $0.024$ — Mixed, T cell network, TLS-like

**E** Resting CD8+ T cells — Kruskal-Wallis, $P < 0.001$; $< 0.001$; $0.0014$ — Mixed, T cell network, TLS-like

**F** Naive B cells — Kruskal-Wallis, $P < 0.001$; $< 0.001$; $< 0.001$ — Mixed, Others, TLS-like

**G** Memory B cells — Kruskal-Wallis, $P < 0.001$; $< 0.001$; $< 0.001$ — Mixed, T cell network, TLS-like

**H** Plasma cells — Kruskal-Wallis, $P < 0.001$; $< 0.001$; $0.0015$ — Mixed, T cell network, TLS-like

**I** Myeloid DCs — Kruskal-Wallis, $P = 0.0029$; $0.0042$ — Mixed, T cell network, TLS-like

**J** Macrophages — Kruskal-Wallis, $P < 0.001$; $< 0.001$; $0.001$ — Mixed, T cell network, TLS-like

**K** M2-like macrophages — Kruskal-Wallis, $P < 0.001$; $< 0.001$; $< 0.001$ — Mixed, T cell network, TLS-like

**I**

CD3

800 µm

60 µm

IgM & IgG

**M**

100 µm

CD20 & CD11c & CD68/CD163

20 µm

20 µm

# Figure S1

**A** Bailur et al.
N=9.623 cells (8 patients)

cDC
Malignant
CD8Tex
CD8Tem
EryPro
B
Monocyte
M1

**B** PDCD1

**C** CTLA4

**D** TIGIT

**E** LAG3

**F**

$r$ = -0.64
$P$ < 0.001

CD8$^+$ cells/mm$^2$

M2-like
macrophage abundance

# Figure S2

**A**
Up in TLS-like aggregate regions (n=20)    Up in mixed regions (n=48)

**B** Activated/Resting CD8+ T cell ratio
Kruskal-Wallis, *P* < 0.001

**C** Plasmacytoid DCs
Kruskal-Wallis, *P* = 0.93

**D** Neutrophils
Kruskal-Wallis, *P* < 0.001

# Figure S3

**A**

**B**